使用SITA-Faster算法量化健康眼、可疑青光眼及青光眼眼的视野变异性及其预测因素
本研究为横断面研究并含前瞻性纵向臂,纳入1426只眼(540只青光眼、753只可疑青光眼、133只健康眼),每只眼接受两次SITA-Faster(SFR)测试。结果显示平均测试-重测差异为2.17±2.9 dB,变异性随阈值敏感度恶化而增加、周边高于中心、随时间稳定;基线MD更差和青光眼半视野测试异常高敏感度是变异性增加的显著预测因素,15%假阳性截断值可能不适合判断SFR测试可靠性。
要点
- SFR平均测试-重测差异为2.17±2.9 dB,平均全局变异为2.17±1.2 dB。
- 变异性随阈值敏感度和MD恶化而增加,周边高于中心,3次随访间稳定(P=0.53)。
- 基线MD(-0.19 dB;95%CI -0.22至0.16 dB;P<0.0001)和GHT异常高敏感度(1.14 dB;95%CI 0.78-1.51 dB;P<0.0001)是变异性增加的显著预测因素。
核心结论
- SFR的变异性随阈值敏感度恶化而增加,随时间稳定,且周边高于中心。
- 基线MD更差和青光眼半视野测试异常高敏感度是变异性增加的显著预测因素。
- 作者认为15%假阳性结果截断值可能不适合作为判断SFR测试可靠性的阈值。
研究设计与样本
- 横断面研究并含前瞻性纵向臂。
- 纳入来自医院和大学眼科诊所的1426只眼(787例患者),包括健康眼、可疑青光眼和确诊青光眼。
- 每只眼在基线访视和两次随访访视各接受两次SFR测试。
主要发现
- 1426只眼中540只(37.9%)诊断为青光眼,753只(52.8%)为可疑青光眼,133只(9.3%)为健康眼。
- 74 152个点敏感度中,平均测试-重测差异为2.17±2.9 dB;每名参与者的平均测试-重测变异为2.17±1.2 dB。
- 纵向队列中3次访视的平均测试-重测变异无显著差异(F0 vs F1 vs F2分别为2.10 dB vs 2.16 dB vs 2.16 dB;P=0.53,重复测量方差分析)。
- 基线MD(-0.19 dB;95%CI -0.22至0.16 dB;P<0.0001)和青光眼半视野测试异常高敏感度(1.14 dB;95%CI 0.78-1.51 dB;P<0.0001)与变异性增加显著相关。
- 测试-重测MD在推荐的15%假阳性截断阈值附近变化极小。
关键数值与推荐
- 点变异性和全局变异性分别随阈值敏感度和MD恶化而增加,且周边测试位置大于中心测试位置。
- 基线MD(-0.19 dB;95%CI -0.22至0.16 dB;P<0.0001)和青光眼半视野测试异常高敏感度(1.14 dB;95%CI 0.78-1.51 dB;P<0.0001)是变异性增加的显著预测因素。
- 3次访视平均测试-重测变异无显著差异(2.10 dB vs 2.16 dB vs 2.16 dB;P=0.53)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The newly released Swedish Interactive Thresholding Algorithm (SITA)-Faster (SFR) has significantly shorter testing durations compared with older SITA algorithms, but its variability is uncertain. This study quantified and established threshold limits of test-retest variability across the 24-2 test grid using SFR. DESIGN: Cross-sectional study with prospective longitudinal arm. PARTICIPANTS: 1426 eyes of 787 patients with healthy, suspected glaucoma, or manifest glaucoma eyes from hospital- and university- eye clinics. METHODS: Two SFR tests per eye at a baseline visit and at two follow-up visits. MAIN OUTCOME MEASURES: Pointwise variability measured by test-retest difference in pointwise sensitivity between tests one and two, mean global variability (test-retest variance) measured by average of pointwise variability for each participant, global sensitivity, and reliability indices of each eye. RESULTS: Of the 1426 eyes, 540 eyes (37.9%) had a diagnosis of glaucoma, 753 eyes (52.8%) were suspected of having glaucoma, and the remaining 133 eyes (9.3%) were healthy. Of 74 152 pointwise sensitivities obtained, the mean test-retest difference was 2.17 ± 2.9 dB, whereas the mean test-retest variance for each participant was 2.17 ± 1.2 dB. Pointwise and global variability increased with worsening threshold sensitivity and (MD), respectively, and was greater for peripheral compared with central test locations. In the longitudinal cohort, no significant difference in mean test-retest variance was found across the 3 visits (mean variability, 2.10 dB vs. 2.16 dB vs. 2.16 dB at visits F0 vs. F1 vs. F2; P = 0.53, repeated-measures analysis of variance). Baseline MD (-0.19 dB; 95% CI, -0.22 to 0.16 dB; P < 0.0001) and abnormally high sensitivity on glaucoma hemifield test (1.14 dB; 95% CI, 0.78-1.51 dB; P < 0.0001) were significantly associated with increased variability. Finally, test-retest MD showed minimal change around the recommended 15% false-positive cutoff threshold. CONCLUSIONS: The variability of SFR increases with worsening threshold sensitivity, is stable over time, and is greater for peripheral compared with central test locations. Worse baseline MD and abnormally high sensitivity are significant predictors of increased variability. A cutoff of 15% in false-positive results may be inappropriate as a threshold for judging test reliability in SFR. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
引用
- Tan JCK, Agar A, Kalloniatis M, et al. Quantification and Predictors of Visual Field Variability in Healthy, Glaucoma Suspect, and Glaucomatous Eyes Using SITA-Faster. Ophthalmology. 2023. PMID: 38110124. doi:10.1016/j.ophtha.2023.12.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。